Is There a Future for AKT Inhibitors in the Treatment of Cancer?
An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2016-06, Vol.22 (11), p.2599-2601 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2601 |
|---|---|
| container_issue | 11 |
| container_start_page | 2599 |
| container_title | Clinical cancer research |
| container_volume | 22 |
| creator | Jansen, Valerie M Mayer, Ingrid A Arteaga, Carlos L |
| description | An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650. |
| doi_str_mv | 10.1158/1078-0432.CCR-16-0100 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4891224</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1808699828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-bc438a0fe770f305273ae92c2845dc2e78ff3b58e21faee7823f72bda804f09a3</originalsourceid><addsrcrecordid>eNqFkU1PwzAMhiMEgjH4CaAcuRScrya98KGKjwkkJDTOUdo5rGhrR9Ii8e9ptQ3BiZNt-fUr2w8hJwzOGVPmgoE2CUjBz_P8JWFpAgxgh4yYUjoRPFW7fb7VHJDDGN8BmGQg98kBTzOdiUyPyPUk0ukcA1JH77q26xPfBHrzOKWTel4VVduESKuatnOk04CuXWLd0sbT3NUlhqsjsufdIuLxJo7J693tNH9Inp7vJ_nNU1JKKdukKKUwDjxqDV6A4lo4zHjJjVSzkqM23otCGeTMO-xLLrzmxcwZkB4yJ8bkcu276oolzsp-i-AWdhWqpQtftnGV_dupq7l9az6tNBnjXPYGZxuD0Hx0GFu7rGKJi4WrsemiZQZMmmWGm_-lw_MAlFa9VK2lZWhiDOh_NmJgB1B2gGAHCLYHZVlqB1D93Onvc36mtmTENwM5jdg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1793900575</pqid></control><display><type>article</type><title>Is There a Future for AKT Inhibitors in the Treatment of Cancer?</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><source>Alma/SFX Local Collection</source><creator>Jansen, Valerie M ; Mayer, Ingrid A ; Arteaga, Carlos L</creator><creatorcontrib>Jansen, Valerie M ; Mayer, Ingrid A ; Arteaga, Carlos L</creatorcontrib><description>An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-16-0100</identifier><identifier>PMID: 26979397</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical cancer research, 2016-06, Vol.22 (11), p.2599-2601</ispartof><rights>2016 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-bc438a0fe770f305273ae92c2845dc2e78ff3b58e21faee7823f72bda804f09a3</citedby><cites>FETCH-LOGICAL-c444t-bc438a0fe770f305273ae92c2845dc2e78ff3b58e21faee7823f72bda804f09a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,3343,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26979397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jansen, Valerie M</creatorcontrib><creatorcontrib>Mayer, Ingrid A</creatorcontrib><creatorcontrib>Arteaga, Carlos L</creatorcontrib><title>Is There a Future for AKT Inhibitors in the Treatment of Cancer?</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650.</description><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkU1PwzAMhiMEgjH4CaAcuRScrya98KGKjwkkJDTOUdo5rGhrR9Ii8e9ptQ3BiZNt-fUr2w8hJwzOGVPmgoE2CUjBz_P8JWFpAgxgh4yYUjoRPFW7fb7VHJDDGN8BmGQg98kBTzOdiUyPyPUk0ukcA1JH77q26xPfBHrzOKWTel4VVduESKuatnOk04CuXWLd0sbT3NUlhqsjsufdIuLxJo7J693tNH9Inp7vJ_nNU1JKKdukKKUwDjxqDV6A4lo4zHjJjVSzkqM23otCGeTMO-xLLrzmxcwZkB4yJ8bkcu276oolzsp-i-AWdhWqpQtftnGV_dupq7l9az6tNBnjXPYGZxuD0Hx0GFu7rGKJi4WrsemiZQZMmmWGm_-lw_MAlFa9VK2lZWhiDOh_NmJgB1B2gGAHCLYHZVlqB1D93Onvc36mtmTENwM5jdg</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Jansen, Valerie M</creator><creator>Mayer, Ingrid A</creator><creator>Arteaga, Carlos L</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20160601</creationdate><title>Is There a Future for AKT Inhibitors in the Treatment of Cancer?</title><author>Jansen, Valerie M ; Mayer, Ingrid A ; Arteaga, Carlos L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-bc438a0fe770f305273ae92c2845dc2e78ff3b58e21faee7823f72bda804f09a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jansen, Valerie M</creatorcontrib><creatorcontrib>Mayer, Ingrid A</creatorcontrib><creatorcontrib>Arteaga, Carlos L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jansen, Valerie M</au><au>Mayer, Ingrid A</au><au>Arteaga, Carlos L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is There a Future for AKT Inhibitors in the Treatment of Cancer?</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>22</volume><issue>11</issue><spage>2599</spage><epage>2601</epage><pages>2599-2601</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650.</abstract><cop>United States</cop><pmid>26979397</pmid><doi>10.1158/1078-0432.CCR-16-0100</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2016-06, Vol.22 (11), p.2599-2601 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4891224 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research; Alma/SFX Local Collection |
| title | Is There a Future for AKT Inhibitors in the Treatment of Cancer? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A03%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20There%20a%20Future%20for%20AKT%20Inhibitors%20in%20the%20Treatment%20of%20Cancer?&rft.jtitle=Clinical%20cancer%20research&rft.au=Jansen,%20Valerie%20M&rft.date=2016-06-01&rft.volume=22&rft.issue=11&rft.spage=2599&rft.epage=2601&rft.pages=2599-2601&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-16-0100&rft_dat=%3Cproquest_pubme%3E1808699828%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1793900575&rft_id=info:pmid/26979397&rfr_iscdi=true |